NCT01081964View on ClinicalTrials.gov

Safety and Efficacy Study of Oral Zabofloxacin in Community Acquired Pneumonia

PHASE2TerminatedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

March 31, 2010

Primary Completion Date

April 30, 2012

Study Completion Date

June 30, 2012

Conditions
Community Acquired Pneumonia
Interventions
DRUG

Zabofloxacin

Zabofloxacin 400mg capsule once daily for 3 days

DRUG

Levofloxacin 500mg

Levofloxacin 500mg orally for 7 days

DRUG

Zabofloxacin 400mg

Zabofloxacin 400mg orally for 5 days

Trial Locations (13)

18974

Warminster

33916

Fort Myers

35773

Toney

35801

Huntsville

43214

Columbus

45432

Dayton

45504

Springfield

47714

Evansville

48320

Keego Harbor

75708

Tyler

93616

Eagle

97030

Gresham

078238

Belvidere

Sponsors

Lead Sponsor

IASO Pharma Inc.
All Listed Sponsors
lead

IASO Pharma Inc.

INDUSTRY